Short answer
KalVista Pharmaceuticals, Inc. (KALV) filed its Q1 2026 10-Q quarterly report on May 14, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $41M with net income of −$23M.
Q1 2026 key financials · XBRL
- Revenue
- $41M
- Net income
- −$23M
- Operating margin
- -57.4%
- EPS (diluted)
- −$0.43
Source: XBRL data from the KalVista Pharmaceuticals, Inc. (KALV) Q1 2026 10-Q on SEC EDGAR. USD.
KalVista Pharmaceuticals, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New transaction risk: Chiesi merger may fail or be delayed, requiring 50%+1 tendered shares and antitrust approvals
- Regulatory risk: HSR Act and foreign investment approvals could delay or prevent closing
- Operational risk: Interim covenants restrict acquisitions, investments, indebtedness, and capital expenditures during the pending merger
- Financial risk: Termination under specified circumstances could require KalVista to pay Chiesi $66.4 million
- Market risk: Prolonged offer period could impair employee retention and relationships with customers, vendors, and collaborators
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other KalVista Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.